Physician profile
Kimberly Vice
NPI 1811543978
$1,511.85
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $54.21 · 2022: $505 · 2023: $716 · 2024: $237.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $841 · Education: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $841.44 |
| Education | $111.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $285.34 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $209.03 | 2022-2023 | |
| Mayne Pharma Commercial LLC | $153.55 | 2022-2023 | |
| Hologic Sales and Service, LLC | $137.67 | 2022-2024 | Aptima, Acessa Provu System, Novasure |
| Astellas Pharma US INC | $124.47 | 2023-2024 | Veozah |
| Sumitomo Pharma America, INC. | $93.82 | 2023 | Myfembree |
| Organon LLC | $90.17 | 2022-2024 | Nexplanon |
| Pfizer INC. | $81.47 | 2023-2024 | |
| Daiichi Sankyo INC. | $38.61 | 2022 | |
| Mylan Pharmaceuticals INC. | $38.47 | 2022 | |
| Baxter Healthcare | $36.26 | 2023 | |
| Evofem Biosciences, INC. | $33.86 | 2023 | Phexxi |
| Sage Therapeutics, LLC | $27.18 | 2023 | |
| Myriad Women'S Health, INC. | $26.83 | 2023 | Myrisk |
| Millicent US INC | $26.70 | 2023 | Femring |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $25.09 | 2024 | Gardasil 9, Gardasil |
| Shield Therapeutics INC | $23.72 | 2024 | |
| Dexcom, INC. | $23.23 | 2023 | Dexcom G6 Transmitter |
| Myovant Sciences INC. | $22.09 | 2022 | |
| Coopersurgical, INC. | $14.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Vice listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.